PMI appoints Matthew Holman as Vice President of Regulatory Strategy

Sep.20.2022
PMI appoints Matthew Holman as Vice President of Regulatory Strategy
Matthew Holman leaves FDA role to become PMI's US Science Engagement and Regulatory Strategy VP as the company seeks to promote safer nicotine alternatives.

Matthew Holman has left his position at the FDA to become the Vice President of Scientific Engagement and Regulatory Strategy for PMI in the United States.


Of course, considering the tobacco companies are currently facing strict regulations and public scrutiny, these appointments are crucial. Badrul Chowdhury, who has worked at the FDA for over 20 years, has accepted the position of Chief Life Sciences Officer, while Matthew Holman has been appointed as Vice President of Science Engagement and Regulatory Strategy for the tobacco company in the United States.


In recent years, Philip Morris International (PMI) has been making efforts to improve its image and reputation by turning towards the sale of safer nicotine alternatives. Former CEO Andre Catantzopoulos believed that a smokeless future is possible and that achieving a consensus with the government and society is necessary through proper supervision and regulation. He stated that alternative nicotine products can be a part of effective tobacco policy. "Thanks to rapid progress in science and technology, and PMI's firm commitment, these products have now become a reality," he said.


Although current CEO of PMI, Jacek Olczak, has stated that the tobacco company intends to achieve its goal of 50% smoke-free product sales by 2025, he also claims the company is fully capable of replacing cigarettes with safer alternatives. "We have a leading portfolio of traditional and smoke-free tobacco products, an excellent management team, and an agile, efficient, and quick-learning organization. We are fully capable of continuing to succeed in our vision of replacing cigarettes with better alternatives for the benefit of consumers, shareholders, and society," he stated earlier this year, quoted by The Edge.


PMI is working hard to change its image.


Last year, PMI received criticism from the British Asthma Association and British Lung Foundation for their collaboration with asthma inhaler manufacturer Vectura. This move appeared hypocritical, as the investment was in a product that could help treat tobacco-related diseases.


Meanwhile, Altria has recently reiterated its plan to enter the healthcare field, stating that this is a natural evolution for tobacco companies. "This is a natural evolution for PMI to further transform our business into a more holistic lifestyle, consumer health, and healthcare company in the future. This evolution is not only fulfilling our continued commitment to a smoke-free future but also fulfilling the development and commercialization of scientifically validated products and solutions to meet unmet consumer and patient needs.


The market for health and wellness products is vast and constantly expanding. We have several key areas of focus in our pipeline. For consumers and over-the-counter healthcare products, we have several initiatives focused on concentration, sleep, energy, pain relief, and calmness. In the healthcare field, we believe that patients' demand for fast and effective treatments for cardiovascular diseases such as myocardial infarction and neurological conditions such as migraines has yet to be met, and innovative solutions can meet these needs. We recently accelerated this part of our strategy through the acquisition of Vectura, an innovative inhalation delivery solution provider, and Fertin, a leading developer and manufacturer of innovative drugs and healthcare products based on oral and intraoral delivery systems," said Alzack.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The compilation of this article is solely for communication and research within the industry.


Due to limitations in translation abilities, the translated article may not fully express the original text, so please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regards to any statements or positions relating to domestic issues, Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Philip Morris Japan (PMJ) launched the limited-edition IQOS ILUMA i PRIME Soundsorial Model in collaboration with French audio brand DEVIALET on October 1, 2026. Featuring sound-wave patterns, a silver-and-black finish and a gradient holder, the heated tobacco device is priced at JPY 15,980, including tax, and is available at four IQOS stores in Japan. According to Japanese media citing a PMJ representative, about 1,900 units were allocated to the Japanese retail market. A separate Soundsorial Collection, combining the device with DEVIALET Gemini II earbuds, includes 440 sets allocated to Japan for a membership prize draw.
product
Oct.23
Special report|Indonesia's Vape Industry Has 200 Manufacturers and $1.7 Billion in Investment. Could a Regulatory Divide Derail Its Rise as the World's No. 2 Manufacturing Hub After Shenzhen?
Special report|Indonesia's Vape Industry Has 200 Manufacturers and $1.7 Billion in Investment. Could a Regulatory Divide Derail Its Rise as the World's No. 2 Manufacturing Hub After Shenzhen?
Indonesia's Ministry of Industry said at a November 3, 2026, policy forum that the country has about 200 electronic cigarette companies, Rp31 trillion (approximately $1.71 billion) in cumulative industry investment and around 100,000 jobs across the supply chain. The National Narcotics Agency is seeking a comprehensive ban on vape use and circulation, while the industry ministry favors tighter import, product-standard and distribution controls. Indonesia exported approximately $518 million in vaping products in 2025, and Chinese manufacturers including Smoore, GEEKVAPE and Jinjia Group have established local operations. An international logistics specialist interviewed by 2Firsts said more Chinese vape companies began production in Indonesia from the second half of 2025, accompanied by increased shipments of manufacturing equipment and investment in logistics facilities. The regulatory debate comes as Indonesia expands its role in international vaping manufacturing.
Special Report
Nov.05
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Russia has placed shares in four Japan Tobacco International businesses under temporary management, the first such move involving a major global tobacco manufacturer, according to Interfax. JTI held 35.8% of Russia's tobacco market by volume in the first nine months of 2026. While British American Tobacco and Imperial Brands have exited Russia, Philip Morris International continues operating there. As the market changes and diplomatic efforts continue, could international tobacco companies that left Russia eventually return?
Nov.06